傳染病檢體採檢手冊[第二版] | 被動收入的投資秘訣 - 2024年8月
![](https://www.books.com.tw/img/001/066/20/0010662057.jpg)
傳染病檢體採檢手冊[第二版]
本次因應「生物材料管理辦法」、「衛生福利部感染性生物材料管理作業要點」及「感染性生物材料或臨床檢體運輸包裝規定」之發布,爰進行本手冊第二次改版﹔除將(疑似)傳染病病人檢體修正為B類感染性物質,以P650包裝,傳染病檢驗實驗室之生物安全等級提升至第二級外,餘均循往例編排。
In order to complying with announced “Regulations Governing Management of Infectious Biological Materials”, “Ministry of Health and Welfare Operating Guidelines for Management of Infectious Biological Materials” and “Transportation packaging requirements for Infectious Biological Materials or Clinical specimens”, CDC, Taiwan, publishes the second version of this Manual. Beside that the specimens of (suspected) patients with infectious diseases are revised to Class B infectious substances packaged by P650 and the infectious disease diagnostic laboratories are ranked to Biosafety Level 2, the other chapters of this Manual are liable to such arrangement of the first version.
傳染病檢體產檢送驗品質之良窳,攸關檢驗結果正確性,且直接影響病人診治及後續之傳染病防治工作。民國88年行政院衛生署疾病管制局(本屬前身)成立,「傳染病防治法」修正,法定傳染病由11種增為38種,手冊篇幅大為擴增,且於94至103年間,因新增新興傳染病及相關管理法規,進行過六次修正,名稱並修正為「傳染病檢體採檢手冊」,提供各界正確的採檢送驗規範,確保檢驗品質。